Abstract:Patients in their first psychotic episode often respond to antipsychotic medications, with rates of response up to 80%. The OPTIMISE project was a large three-phase multicenter study, which included 446 patients in their first psychotic episode, who received open-label amisulpride, and/or double-blind amisulpride or olanzapine for 10 weeks. Of the patients recruited, 63% went into remission, as defined by the Andreasen criteria. This present study attempted to identify predictors of later relapse in these initial remitters during a follow-up period of up to a year and a half. Relapse was defined by changes of PANSS scores compared to time of remission at any time during the follow-up period using one of two different criteria: (1) ≥ 20% increase in total PANSS score from the time of remission, or (2) no longer meeting one or more of the Andreasen criteria. Potential predictors tested in the analyses were age, sex, duration of untreated psychosis, cannabis use, baseline PANSS scores, and insight, as measured by the drug attitude inventory (DAI) scale and the Knowledge of Psychotic Illness (KPI) Questionnaire. Univariate analyses examining the effect of each of these potential predictors on risk for relapse were performed. Those variables who were significant in the univariate analyses were included in a multivariate logistic regression. When using the 20% increase of PANSS criterion for relapse, a total of 67 out of 446 patients (15%) were included in the analyses, using the criterion of no longer meeting Andreasen criteria identified 101 out of 446 (23%) patients. When using the relapse criterion of 20% increase in PANSS, univariate analyses showed a significant effect on relapse, with lower baseline score increasing risk of relapse: for baseline positive PANSS score (OR=0.918, 95% CI: 0.868–0.971, p=0.003), baseline negative PANSS score (OR=0.926, 95% CI: 0.883–0.972, p=0.002), baseline general psychopathology PANSS score (OR=0.943, 95% CI: 0.911–0.976, p=0.001), and cannabis use (OR=2.284, 95% CI: 1.116–4.678, p=0.024). Multivariate analyses showed significant effects on relapse only for cannabis use (OR=2.011, 95% CI:1.024–4.087, p=0.021). Both univariate and multivariate analyses were not significant when using the relapse criterion of not meeting one or more Andreasen criteria. Cannabis use was the only significant clinical factor that increased risk for relapse. These findings are similar to previous studies which showed a strong correlation between cannabis use and earlier and more frequent relapses. Patients and family members should be made aware of this finding and future studies should investigate the effect of cannabis cessation programs on relapse rates.

Clinical insight level predicts successful quit or control attempts during the first three months of outpatient addiction treatment

Relationship of insight to neurocognitive function and risk of recurrence in depression: A naturalistic follow-up study

Predicting post-treatment-initiation alcohol use among patients with severe mental illness and alcohol use disorders.

Effect of cognitive insight on clinical insight from pre-morbid to early psychosis stages

Relationship Between Cognitive and Clinical Insight at Different Durations of Untreated Attenuated Psychotic Symptoms in High-Risk Individuals.

Anxiety and Suicidal Ideation Predict Successful Completion of Substance Abuse Treatment in a Criminal Justice Sample

Sign-tracking to non-drug reward is related to severity of alcohol-use problems in a sample of individuals seeking treatment

Using conventional and machine learning propensity score methods to examine the effectiveness of 12-step group involvement following inpatient addiction treatment

Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence

17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION

Destination Matters More: Relapse following Hospital-Based Treatment of Substance Use Disorders With and Without Co-Occurring Disorders

Initial attitudes toward a drug predict medication adherence in first-episode patients with schizophrenia: a 1-year prospective study in China

Not Two Sides of the Same Coin: A Qualitative Comparative Analysis of Post-Treatment Abstinence and Relapse

Predictive value of readiness, importance, and confidence in ability to change drinking and smoking

The development of insight and its relationship with suicidality over one year follow-up in patients with first episode psychosis

Smokers with higher positive or negative urgency have lower rates of smoking cessation success 12 months after a quit attempt

Social cognitive predictors of treatment outcome in cannabis dependence

Predictors of substance use during treatment for addiction: A network analysis of ecological momentary assessment data

Impaired insight in cocaine addiction: laboratory evidence and effects on cocaine-seeking behaviour

Abstinence Self-Efficacy and Abstinence 1 Year After Substance Use Disorder Treatment.

Examining the predictive utility of suicidal ideation characteristics in relation to real‐time monitoring of suicidal ideation and suicide attempts at follow‐up